Facts & Figures
Science for a better life - Medical Progress for the Benefit of the Patient
Facts and Figures at a glance
| Research expenses 2008 | 1,742 € million |
| Proportion of total Bayer group research expenses 2008 | 66% |
| Employees in Research & Development | 6,682 (as of Dec. 31, 2008) |
| Main research locations | Berlin and Wuppertal, Germany and Berkeley, USA |
| Research focus |
|
Research activities 2008
In 2008 we invested €1,742 million (2007: €1,700 million) in research and development in the Pharmaceuticals and Consumer Health segments to lay the foundations for the introduction of further innovative products in the subgroup’s expanding markets. This represented about 66 percent of the Bayer Group’s entire research and development expenditures and was equivalent to 11.3 percent of sales.
Research and development in the Pharmaceuticals segment is strategically aligned to the conditions in its markets. In drug discovery we focus on four growth areas: diagnostic imaging, cardiology, oncology, and women’s healthcare. The respective research activities and capacities are concentrated at three sites in Berlin and Wuppertal, Germany, and Berkeley, California. Work at the Berlin and Wuppertal sites focuses on identifying molecular targets in order to develop and optimize lead substances. Research is also carried out at these sites in the fields of drug metabolism, pharmacokinetics, toxicology and clinical pharmacology. Berkeley is an important global research and development center for protein-based active ingredients and is home to the biotechnological production facility for Kogenate®.
Research locations
The Berlin and Wuppertal locations have significant capabilities and activities in the identifi cation of molecular targets and the development and optimization of lead substances, as well as in drug metabolism, pharmacokinetics, toxicology and clinical pharmacology.
Berkeley is an important global research and development center for protein-based active ingredients and is home to the biotechnological production facility for Kogenate®. Bayer HealthCare’s u.s. research sites in West Haven, Connecticut, and Richmond, California, have been or will be closed.